Source-grounded facts extracted from BIOLIFE SOLUTIONS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
BIOLIFE SOLUTIONS INC reported the three months ended March 31, 2026 results: revenue $27.5 million, net income $1.2 million, EPS $0.02. Guidance reaffirmed.
“BioLife Solutions Reports First Quarter 2026 Financial Results Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue”
Catherine Coste was appointed as Director and Audit Committee Chair at BIOLIFE SOLUTIONS INC.
“Effective March 18, 2025, the board of directors (the “Board”) of BioLife Solutions, Inc. (the “Company”) appointed Catherine Coste to serve as a member of the Board until the Company’s 2025 Annual Meeting of Stockholders”
BIOLIFE SOLUTIONS INC completed a disposition involving Standex International Corporation for approximately $6.1 million (closed 2024-11-14).
““CBS”), for the sale by the Company of all of the issued and outstanding shares of common stock (the “Shares”) of CBS to Buyer for an aggregate purchase price of approximately $6.1 million (subject to adjustment as set forth in the Purchase Agreement) (the “Transaction”). Following the execution of the Purchase Agreement, the Transaction was consummated on November”
BIOLIFE SOLUTIONS INC: On November 12, 2024, the Company amended and restated its bylaws to make certain updates and revisions, including provisions about meeting adjournments, quorum requirements, record dates, meeting conduct, advance notice for stockholder proposals, director vacancies, officer positions, indemnificati (effective 2024-11-12).
“On November 12, 2024, the Company amended and restated its bylaws to make certain updates and revisions (the “Amended and Restated Bylaws”).”
BIOLIFE SOLUTIONS INC completed a disposition involving Subzero Purchaser Corp. for $73.0 million (closed 2024-11-12).
“for the sale by Seller of all of the issued and outstanding shares of common stock (the “Shares”) of SciSafe to Buyer for an aggregate purchase price of $73.0 million”
BIOLIFE SOLUTIONS INC reported first quarter ended March 31, 2024 results: revenue $31.7 million, net income $10.2 million, EPS $0.22. Guidance reaffirmed.
“51 % Adjusted Gross Margin 53 % Net Loss $ (4,453) Adjusted EBITDA $ 3,583 Adjusted EBITDA as a % of Revenue 13 % REVENUE • Total revenue for the first quarter of 2024 was $31.7 million, a decrease of $6.0 million, or 16%, from $37.7 million for the first quarter of 2023 and down $1.0 million, or 3%, sequentially from the fourth quarter of 2023. ◦ Cell”
BIOLIFE SOLUTIONS INC completed a disposition involving GCI Holdings Company, LLC for $1.00 (closed 2024-04-17).
“tock Purchase Agreement for Global Cooling Divestiture On April 17, 2024, BioLife Solutions, Inc., a Delaware corporation (the “Company”), entered into a Stock Purchase Agreement, dated April 17, 2024 (the “Purchase Agreement”), by and between the Company and GCI Holdings Company, LLC, an Ohio limited liability company that is wholly owned by an employee of Global Cooling (as defined below) (“Buyer”), for the sale of all of the issued and outstanding shares of common stock (the “Shares”) of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to Buyer for an aggregate purchase price of $1.00 (the “Transaction”).”
BIOLIFE SOLUTIONS INC entered into Consent and Second Amendment to Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (effective 2024-04-17).
“On April 17, 2024, the Company entered into a Consent and Second Amendment to Loan and Security Agreement, dated April 17, 2024 (the “Amendment”), by and among Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (“Bank”), the Company, SAVSU Technologies, Inc., a Delaware corporation (“SAVSU”), Arctic Solutions, Inc., a Delaware corporation doing business as Custom Biogenic Systems (“Arctic”), SciSafe Holdings, Inc., a Delaware corporation (“SciSafe”), Global Cooling, and Sexton Biotechnologies, Inc., a Delaware corporation (“Sexton,” and together with the Company, SAVSU, Arctic, SciSafe, and Global Cooling, “Borrower”).”
BIOLIFE SOLUTIONS INC entered into Stock Purchase Agreement with GCI Holdings Company, LLC valued at $1.00 (effective 2024-04-17).
“on April 17, 2024, BioLife Solutions, Inc., a Delaware corporation (the “Company”), entered into a Stock Purchase Agreement, dated April 17, 2024 (the “Purchase Agreement”), by and between the Company and GCI Holdings Company, LLC, an Ohio limited liability company that is wholly owned by an employee of Global Cooling (as defined below) (“Buyer”), for the sale of all of the issued and outstanding shares of common stock (the “Shares”) of Global Cooling, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Global Cooling”), to Buyer for an aggregate purchase price of $1.00 (the “Transaction”).”
BIOLIFE SOLUTIONS INC announced a restructuring with charges of approximately $2.5 million of charges affecting Global Cooling, Inc. (approximately 47 employees (representing approximately 11% of its full-time employees)).
“on March 29, 2024, and all affected employees were informed on April 17, 2024, following the execution of the Purchase Agreement. The Company expects to recognize approximately $2.5 million of charges in connection with the RIF, comprised of approximately $2.0 million of stock compensation expense and approximately $0.5 million in cash expenditures, substantially”
BIOLIFE SOLUTIONS INC updated its the fourth quarter and year ended December 31, 2023 guidance (initiated).
“On February 29, 2024, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing financial results and operational highlights for the fourth quarter and year ended December 31, 2023.”
BIOLIFE SOLUTIONS INC reported the full year 2023 results: revenue $143.3 million.
“Preliminary and unaudited revenue for the full year 2023 was $143.3 million”
BIOLIFE SOLUTIONS INC reported the fourth quarter of 2023 results: revenue $32.7 million.
“Preliminary and unaudited revenue for the fourth quarter of 2023 was $32.7 million”
BIOLIFE SOLUTIONS INC reported third quarter ended September 30, 2023 results: revenue $33.3 million, net income Net loss (GAAP) for the third quarter of 2023 was $29.1 million, EPS Loss per share (GAAP) for the third quarter of 2023 was $0.67. Guidance reaffirmed.
“news release. 3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com REVENUE • Total revenue for the third quarter of 2023 was $33.3 million, a decrease of $7.4 million, or 18%, from $40.7 million for the third quarter of 2022. There was no COVID related revenue in the third quarter of 2023. Ex-COVID related revenue”
BIOLIFE SOLUTIONS INC reported the quarter ended September 30, 2023 results: revenue $33.3 million. Guidance reaffirmed.
“Q3 Preliminary Unaudited Revenue and Updated FY2023 Guidance The Company is reporting preliminary, unaudited revenue for the third quarter of 2023 of approximately $33.3 million.”
Roderick de Greef was appointed as President and Chief Executive Officer and Chairman at BIOLIFE SOLUTIONS INC.
“On October 19, 2023, the Board appointed Roderick de Greef as the President and Chief Executive Officer of the Company (Principal Executive Officer) and Chairman of the Board, effective immediately.”
Michael Rice resigned as Chief Executive Officer and Chairman at BIOLIFE SOLUTIONS INC.
“On October 19, 2023, Michael Rice, the Chief Executive Officer and Chairman of the Board of Directors (the “Board”) of the Company, resigned his positions as Chairman of the Board and Chief Executive Officer of the Company, effective immediately.”
BIOLIFE SOLUTIONS INC entered into Securities Purchase Agreement with Casdin Partners Master Fund, L.P. valued at $10,374,976.35 (effective 2023-10-19).
“On October 19, 2023, BioLife Solutions, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Casdin Partners Master Fund, L.P. (the “Purchaser”), whereby the Company will sell, and the Purchaser will purchase, 927,165 shares of common stock of the Company, par value $0.001 per share (the “Securities”), at a purchase price of $11.19 per share for an aggregate purchase price of $10,374,976.35”
BIOLIFE SOLUTIONS INC updated its second quarter ended June 30, 2023 guidance (reaffirmed).
“On August 8, 2023, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing unaudited financial results and operational highlights for the second quarter ended June 30, 2023.”
BIOLIFE SOLUTIONS INC shareholders approved Approval of the 2023 Omnibus Performance Incentive Plan at the 2023-07-21 meeting.
“Proposal No. 4 - Approval of the 2023 Omnibus Performance Incentive Plan . The 2023 Omnibus Performance Incentive Plan was approved.”
BIOLIFE SOLUTIONS INC shareholders approved Ratification of the appointment by the Board of the Company of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-07-21 meeting.
“Proposal No. 3 - Ratification of the appointment by the Board of the Company of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
BIOLIFE SOLUTIONS INC shareholders approved Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers at the 2023-07-21 meeting.
“Proposal No. 2 - Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers. The compensation for the Company’s named executive officers, by non-binding advisory vote, was approved.”
BIOLIFE SOLUTIONS INC shareholders approved Election of directors: Michael Rice, Joydeep Goswami, Joseph Schick, Amy DuRoss, Rachel Ellingson, Roderick de Greef, and Timothy Moore at the 2023-07-21 meeting.
“Proposal No. 1 - Election of directors . Michael Rice, Joydeep Goswami, Joseph Schick, Amy DuRoss, Rachel Ellingson, Roderick de Greef, and Timothy Moore were elected to serve until the 2024 annual meeting of stockholders or until his or her successor is duly elected and qualified or until his or her earlier resignation or removal or otherwise is disqualified from serving as a director of the Company.”
BIOLIFE SOLUTIONS INC reported preliminary financial results for the fourth quarter and year ended December 31, 2022.
“On March 16, 2023, BioLife Solutions, Inc., a Delaware corporation, issued a press release announcing unaudited financial results and operational highlights for the fourth quarter and year ended December 31, 2022.”
BIOLIFE SOLUTIONS INC reported the three and nine months ended September 30, 2022 results: revenue Total revenue for the third quarter of 2022 was $40.7 million. Guidance reaffirmed.
“On November 9, 2022, BioLife Solutions, Inc. issued a press release announcing financial results and operational highlights for the third quarter ended September 30, 2022.”
Geraint Phillips changed role as Senior Vice President, Global Operations at BIOLIFE SOLUTIONS INC.
“On September 30, 2022, the Company announced that effective January 3, 2022, Geraint Phillips, the current Vice President of Freezer Operations, will be promoted to Senior Vice President, Global Operations of the Company to assume many of the responsibilities currently held by Mr. de Greef.”
Roderick de Greef was appointed as Director at BIOLIFE SOLUTIONS INC.
“The Board of Directors of the Company (the “Board”) will appoint Mr. de Greef to the Board as a director concurrently with his resignation.”
Roderick de Greef departed as President and Chief Operating Officer at BIOLIFE SOLUTIONS INC.
“On September 30, 2022, Roderick de Greef, the President and Chief Operating Officer of BioLife Solutions, Inc. (the “Company”), notified the Company of his intent to retire from his positions as President and Chief Operating Officer, effective January 3, 2022.”
Tim Moore was appointed as Director at BIOLIFE SOLUTIONS INC.
“Effective September 1, 2022, the board of directors (the “Board”) of BioLife Solutions, Inc. (the “Company”) appointed Tim Moore to the Board”
Roderick de Greef was appointed as President and Chief Operating Officer at BIOLIFE SOLUTIONS INC.
“On November 4, 2021, the Company appointed Troy Wichterman as Chief Financial Officer and Roderick de Greef as President and Chief Operating Officer.”
Troy Wichterman was appointed as Chief Financial Officer at BIOLIFE SOLUTIONS INC.
“On November 4, 2021, the Company appointed Troy Wichterman as Chief Financial Officer”
Maurice 'Dusty' Tenney resigned as Chief Operating Officer at BIOLIFE SOLUTIONS INC.
“On November 3, 2021, Maurice “Dusty” Tenney, the Chief Operating Officer of BioLife Solutions, Inc. (the “Company”), notified the Company of his intent to resign as Chief Operating Officer, effective immediately.”
Joydeep Goswami was appointed as Director at BIOLIFE SOLUTIONS INC.
“the Board appointed Joydeep Goswami, Ph.D. to the Board”
Andrew Hinson retired as Director at BIOLIFE SOLUTIONS INC.
“Effective October 1, 2021, Andrew Hinson retired from the board of directors”
Roderick de Greef retired as Chief Financial Officer at BIOLIFE SOLUTIONS INC.
“On September 14, 2021, Roderick de Greef, the Chief Financial Officer of BioLife Solutions, Inc. (the “Company”), notified the Company of his intent to retire from his position as Chief Financial Officer, effective December 31, 2021.”
Michael Rice was appointed as Chairman of the Board of Directors at BIOLIFE SOLUTIONS INC.
“appointed Michael Rice, the Chief Executive Officer and a director of the Company, as Chairman of the Board of Directors”
Raymond Cohen resigned as Chairman of the Board of Directors at BIOLIFE SOLUTIONS INC.
“On July 12, 2021, Raymond Cohen, the Chairman of the Board of Directors of BioLife Solutions, Inc. (the “Company”), resigned from the Board of Directors and all committees thereto.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.